<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04057807</url>
  </required_header>
  <id_info>
    <org_study_id>1611018611</org_study_id>
    <nct_id>NCT04057807</nct_id>
  </id_info>
  <brief_title>Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease</brief_title>
  <official_title>PBR28 Brain Positron Emission Tomography Imaging With Lipopolysaccharide (LPS) Challenge for the Study of Microglia Function in Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine the differences in the capacity to activate microglia in patients with Alzheimer's
      Disease (AD) compared to age-comparable cognitively normal subjects and younger healthy
      controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary outcome is Microglia Activation Reserve Index (MARI) (calculated in the parietal
      region of interest (ROIs)) in AD patients compared to elderly controls. The researchers will
      recruit up to 20 participants. The investigators will use 7 AD and 7 comparably aged
      cognitively normal successfully scanned subjects to calculate the microglial activation
      reserve index. The expectations are significant differences between the two groups suggesting
      altered reactivity of the microglia in AD. The result would be an exciting one suggesting at
      least one mechanism by which some patients with significant amyloid load have progressive
      dementia while comparable others are either cognitively normal or have stable Mild Cognitive
      Impairment (MCI). It will also suggest avenues for intervention in amyloid positive MCIs to
      prevent progression to Alzheimer's dementia. The exploratory analysis will include:

        1. Effects of aging on MARI: The researchers will evaluate the effects of aging on MARI.
           Comparisons will be made for MARI between cognitively normal elderly and the 8 healthy
           individuals to whom the investigators applied this protocol in an earlier study. The
           reactivity of microglia is reported to change with age and so the investigators expect
           MARI to change in the cognitively normal elderly. However, the expectation is that the
           differences between the young and elderly cognitively normal subjects to be small
           relative to the comparison of AD and elderly normal controls.

        2. Effects of amyloid on MARI: The researchers will look at the relationship of regional
           and global amyloid load to MARI. The presence of a relationship suggests that one of the
           reasons for altered microglial reactivity might be interactions of microglia with
           pathologic amyloid.

        3. Effects of MARI on cognition: The researchers will explore whether MARI would correlate
           with the measure of disease stage, with higher MARIs associated with worse
           neuropsychological score and more severe disease. The researchers will look for
           correlations between MARI and the individual neuropsychological scores. This would
           determine if disease severity is correlated with microglial activation reserve.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2017</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>An altered reactivity of microglia</measure>
    <time_frame>180 minutes post intervention</time_frame>
    <description>Th primary outcome is MARI (calculated in the parietal ROIs) in AD patients compared to elderly controls. The investigators will use 7 AD and 7 comparably aged cognitively normal successfully scanned subjects to calculate the microglial activation reserve index. It is expected that there will be significant differences between the two groups suggesting Altered reactivity of the microglia in AD.The result would be an exciting one suggesting at least one mechanism by which some patients with significant amyloid load have progressive dementia while comparable others are either cognitively normal or have stable MCI. It will also suggest avenues for intervention in amyloid positive MCIs to prevent progression to Alzheimer's dementia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of aging on MARI</measure>
    <time_frame>180 minutes post intervention</time_frame>
    <description>The investigators will evaluate the effects of aging on MARI. Comparisons will be made for MARI between cognitively normal elderly and the 8 healthy individual to whom the researchers applied this protocol in an earlier study. The reactivity of microglia is reported to change with age (11) and so MARI is expected to change in the cognitively normal elderly. However, it is expected that the differences between the young and elderly cognitively normal subjects to be small relative to the comparison of AD and elderly normal controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of amyloid on MARI</measure>
    <time_frame>180 minutes post intervention</time_frame>
    <description>The investigators will look at the relationship of regional and global amyloid load to MARI. The presence of a relationship suggests that one of the reasons for altered microglial reactivity might be interactions of microglia with pathologic amyloid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of MARI on cognition</measure>
    <time_frame>180 minutes post intervention</time_frame>
    <description>The investigators will explore whether MARI would correlate with measure of disease stage, with higher MARIs associated with worse neuropsychological score and more severe disease. The investigators will look for correlations between MARI and the individual neuropsychological scores. This would determine if disease severity is correlated with microglial activation reserve.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Patients receiving endotoxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 20 enrolled subjects will have LPS (0.4 ng/kg) administered intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LPS</intervention_name>
    <description>LPS (0.4 ng/kg)</description>
    <arm_group_label>Patients receiving endotoxin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild AD Subjects:

          -  National Institute on Aging (NIA)-Alzheimer's Association core clinical criteria for
             probable AD

          -  Age between 55 and 90 (inclusive)

          -  Score on the Montreal Cognitive Assessment (MOCA) greater than or equal to 17

          -  Presence of a responsible caregiver who will accompany AD subjects to all procedures.

          -  Biomarker evidence of Alzheimer's disease via an amyloid PET scan or cerebrospinal
             fluid (CSF) amyloid Beta measurement.

          -  The patient should have the capacity to consent.

          -  Clinical Dementia Rating (CDR) global score greater than 0.

          -  Cognitively normal elderly Subjects:

          -  Absence of National Institute on Aging-Alzheimer's Association core clinical criteria
             for probable AD

          -  Objective memory scores within the normal range for age (do not meet MCI Subjects
             criterion 2)

          -  Age between 55 and 90 (inclusive)

          -  Clinical Dementia Rating (CDR) global score of 0.0

        Exclusion Criteria:

          -  Any significant neurologic disease (other than probable AD in the AD Subjects group),
             such as stroke, Parkinson's disease, brain tumor, seizure disorder, multiple
             sclerosis, or history of significant head trauma followed by persistent neurologic
             deficits.

          -  Any significant systemic disease including hepatic failure, heart failure, renal
             failure, chronic obstructive pulmonary disease (COPD), active infection and autoimmune
             disease.

          -  Screening/baseline MRI scan with evidence of infection, infarction, or other focal
             lesions. Subjects with multiple lacunes or lacunes in a critical memory structure are
             excluded.

          -  Any significant systemic illness or unstable medical condition, including uncontrolled
             or insulin- dependent diabetes mellitus, uncorrected hypothyroidism or
             hyperthyroidism, or systemic cancer.

          -  Current or regular use of over-the-counter medication that may affect the immune
             system (e.g., ibuprofen), including corticosteroids or immunosuppressant drugs; no use
             in 3 weeks prior to the PET scan

          -  Investigational agents are prohibited 4 weeks prior to entry and for the duration of
             the study.

          -  Previous treatment with an investigational small molecule with anti-amyloid properties
             or passive immunization against amyloid within 1 year of study entry.

          -  Previous treatment with an active immunization against amyloid.

          -  History of schizophrenia or other major psychiatric disorder (DSM IV criteria).

          -  History of alcohol or substance abuse or dependence (DSM IV criteria) within the past
             2 years.

          -  Clinically significant abnormalities on screening laboratory tests (B12, Thyroid
             function tests, hematology, chemistry, urinalysis, ECG).

          -  Pregnancy, as determined by screening pregnancy tests for pre-menopausal females

          -  Impairment of visual or auditory acuity sufficient to interfere with study procedures.

          -  Education level &lt; 6 years.

          -  Evidence of current depression as defined by a score of â‰¥ 5 on the Geriatric
             Depression Scale.

          -  Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal
             fragments or foreign objects in the eyes, skin or body. The presence of
             claustrophobia, precluding MRI.

          -  Current or recent participation in any procedures involving radioactive agents such
             that the total radiation dose exposure to the subject in any given year would exceed
             the limits of annual and total dose commitment set forth in the US Code of Federal
             Regulations (CFR) Title 21 Section 361.1.

          -  Vaccination in the last month.

          -  Drink more than 5 alcoholic drinks per week or any heavy drinking days in the last 30
             days.

          -  BMI &gt; 35 or &lt; 19

          -  Women who are pregnant or nursing, or fail to use one of the following methods of
             birth control unless she or partner is surgically sterile or she is postmenopausal
             (hormone contraceptives [oral, implant, injection, patch, or ring], contraceptive
             sponge, double barrier [diaphragm or condom plus spermicide], or Intrauterine Device
             (IUD)

          -  Individuals who are classified as &quot;low binders&quot; for the rs6971 polymorphism (&lt;10% of
             the population)

          -  Patients on antiplatelet and anticoagulant medications will be excluded.

          -  Any patient without the capacity to consent will be excluded.

          -  Unstable hypertension. If blood pressure is greater than 160/100, the investigators
             will contact the subject's primary care physician to manage their blood pressure. If
             their blood pressure is not reduced to be consistently below 160/100 by the scanning
             day the subject will be excluded from the protocol.

          -  Patients with contraindications for lumbar puncture procedure can be still involved
             and will be excluded from the optional portion of the study with the lumbar puncture.
             These include existing intracranial space-occupying lesion with mass effect, posterior
             fossa mass, risk of cerebral herniation by increased CSF pressure or Arnold chiari
             malformation, as well as anticoagulant medication, coagulopathies and uncorrected
             bleeding diathesis, congenital spine abnormalities, and local skin infection at the
             puncture site.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arash Salardini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arsalan Hashemiaghdam, MD</last_name>
    <phone>203-785-7393</phone>
    <email>arsalan.hashemi@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alzheimer's Disease Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Harris</last_name>
      <phone>203-764-8100</phone>
    </contact>
    <contact_backup>
      <last_name>Arsalan Hashemiaghdam</last_name>
      <phone>203-785-7393</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 13, 2019</study_first_submitted>
  <study_first_submitted_qc>August 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2019</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

